TY - JOUR
T1 - Network correlates of disease severity in multiple system atrophy
AU - Poston, K. L.
AU - Tang, C. C.
AU - Eckert, T.
AU - Dhawan, V.
AU - Frucht, S.
AU - Vonsattel, J. P.
AU - Fahn, S.
AU - Eidelberg, D.
N1 - Funding Information:
Study funding: Supported by the NIH (NINDS R01 NS 35069 and P50 NS 071675) to D.E. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIH.
Funding Information:
Dr. Poston has received research support from Neurologix, Inc., Ceregene, Inc., and the NIH/NINDS. Dr. Tang has received research support from the NIH/NINDS and Neurologix, Inc. Dr. Eckert reports no disclosures. Dr. Dhawan has received research support from the NIH (NIDCD, NIAID, NINDS), Dana Foundation, and Neurologix, Inc. Dr. Frucht has received funding for travel or speaker honoraria from Jazz Pharmaceuticals, Lundbeck, Inc., and Merz Pharmaceuticals, LLC; receives publishing royalties for Movement Disorders Emergencies: Diagnosis and Treatment (Humana Press, 2005); and serves/has served as a consultant for UCB, Jazz Pharmaceuticals, Merz Pharmaceuticals, LLC, GE Healthcare, and Allergan, Inc. Dr. Vonsattel receives research support from the NIH/NIA, The Hereditary Disease Foundation, and The Louis and Rachel Rudin Foundation. Dr. Fahn serves on scientific advisory boards for Intech Pharma Pvt. Ltd., IMPAX Laboratories, Inc., Civitas, RJG Foundation, and Lundbeck, Inc.; serves as Co-editor of Current Neurology and Neurosurgery Report; receives publishing royalties for Principles and Practice of Movement Disorders (Elsevier, 2007); serves as a consultant for Green Cross Corporation of Korea and Genervon Laboratories; and receives research support from the US Department of Defense's Telemedicine and Advanced Technology Research Center (TATRC), the NIH, the Parkinson's Disease Foundation, and the Smart Family Foundation. Dr. Eidelberg serves on scientific advisory boards for and has received honoraria from the Thomas Hartman Foundation for Parkinson's Research, Inc., the Michael J. Fox Foundation, and the Bachmann-Strauss Dystonia and Parkinson Foundation; has served as a consultant for Neurologix, Inc. and Merck & Co., Inc.; serves on the editorial boards of Annals of Neurology and NeuroImage and as an Associate Editor of the Journal of Neuroscience and Molecular Imaging and Biology; is listed as coinventor of patents on the use of imaging markers to screen patients for nervous system dysfunction; and has received research support from the NIH (NINDS, NCRR, NIDCD, NIAID), the Dana Foundation, the Bachmann-Strauss Dystonia and Parkinson Foundation, and the CHDI Foundation.
PY - 2012/4/17
Y1 - 2012/4/17
N2 - Objective: Multiple system atrophy (MSA), the most common of the atypical parkinsonian disorders, is characterized by the presence of an abnormal spatial covariance pattern in resting state metabolic brain images from patients with this disease. Nonetheless, the potential utility of this pattern as a MSA biomarker is contingent upon its specificity for this disorder and its relationship to clinical disability in individual patients. Methods: We used [18F]fluorodeoxyglucose PET to study 33 patients with MSA, 20 age- and severity-matched patients with idiopathic Parkinson disease (PD), and 15 healthy volunteers. For each subject, we computed the expression of the previously characterized metabolic covariance patterns for MSA and PD (termed MSARP and PDRP, respectively) on a prospective single-case basis. The resulting network values for the individual patients were correlated with clinical motor ratings and disease duration. Results: In the MSA group, disease-related pattern (MSARP) values were elevated relative to the control and PD groups (p < 0.001 for both comparisons). In this group, MSARP values correlated with clinical ratings of motor disability (r - 0.57, p - 0.0008) and with disease duration (r = -0.376, p = 0.03). By contrast, MSARP expression in the PD group did not differ from control values (p = 1.0). In this group, motor ratings correlated with PDRP (r = 0.60, p = 0.006) but not with MSARP values (p = 0.88). Conclusions: MSA is associated with elevated expression of a specific disease-related metabolic pattern. Moreover, differences in the expression of this pattern in patients with MSA correlate with clinical disability. The findings suggest that the MSARP may be a useful biomarker in trials of new therapies for this disorder.
AB - Objective: Multiple system atrophy (MSA), the most common of the atypical parkinsonian disorders, is characterized by the presence of an abnormal spatial covariance pattern in resting state metabolic brain images from patients with this disease. Nonetheless, the potential utility of this pattern as a MSA biomarker is contingent upon its specificity for this disorder and its relationship to clinical disability in individual patients. Methods: We used [18F]fluorodeoxyglucose PET to study 33 patients with MSA, 20 age- and severity-matched patients with idiopathic Parkinson disease (PD), and 15 healthy volunteers. For each subject, we computed the expression of the previously characterized metabolic covariance patterns for MSA and PD (termed MSARP and PDRP, respectively) on a prospective single-case basis. The resulting network values for the individual patients were correlated with clinical motor ratings and disease duration. Results: In the MSA group, disease-related pattern (MSARP) values were elevated relative to the control and PD groups (p < 0.001 for both comparisons). In this group, MSARP values correlated with clinical ratings of motor disability (r - 0.57, p - 0.0008) and with disease duration (r = -0.376, p = 0.03). By contrast, MSARP expression in the PD group did not differ from control values (p = 1.0). In this group, motor ratings correlated with PDRP (r = 0.60, p = 0.006) but not with MSARP values (p = 0.88). Conclusions: MSA is associated with elevated expression of a specific disease-related metabolic pattern. Moreover, differences in the expression of this pattern in patients with MSA correlate with clinical disability. The findings suggest that the MSARP may be a useful biomarker in trials of new therapies for this disorder.
UR - https://www.scopus.com/pages/publications/84860755196
U2 - 10.1212/WNL.0b013e318250d7fd
DO - 10.1212/WNL.0b013e318250d7fd
M3 - Article
AN - SCOPUS:84860755196
SN - 0028-3878
VL - 78
SP - 1237
EP - 1244
JO - Neurology
JF - Neurology
IS - 16
ER -